Literature DB >> 19038365

The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.

Kristof Theys1, Jurgen Vercauteren, Ana B Abecasis, Pieter Libin, Koen Deforche, Anne-Mieke Vandamme, Ricardo Camacho.   

Abstract

OBJECTIVE: The overall prevalence of the K65R mutation in HIV-1 reverse transcriptase has increased in treatment-experienced patients, mostly attributed to the increasing use of tenofovir (TDF). A number of TDF-based regimens are associated with high rate of early virological failure. In this study, we evaluated the impact of these combinations on K65R selection over time.
METHODS: Treatment-experienced patients who had a genotypic resistance test at time of failure in the period 2002-2005 in a hospital in Lisbon were included. Incidence of K65R was calculated and compared with proportions of failing therapies in the respective year of sampling including TDF or didanosine plus stavudine and their respective frequency of K65R selection were analyzed using classical statistics and Bayesian Network Learning.
RESULTS: The overall rate of K65R in the database was consistent with earlier reports. The incidence of K65R increased in the period 2002-2004 but showed a sharp, significant decrease in 2005, despite a continuous increase of patients failing TDF-based regimens. The proportion of patients failing certain not-recommended regimens decreased sharply in 2005 and therefore correlated well with K65R incidence trend.
CONCLUSIONS: This study suggests that the use of certain TDF-based regimens caused the increase in K65R incidence over the last years.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19038365     DOI: 10.1016/j.meegid.2008.10.013

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  5 in total

1.  HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.

Authors:  K Theys; J Vercauteren; J Snoeck; M Zazzi; R J Camacho; C Torti; E Schülter; B Clotet; A Sönnerborg; A De Luca; Z Grossman; D Struck; A-M Vandamme; A B Abecasis
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

2.  Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.

Authors:  K Theys; J Snoeck; J Vercauteren; A B Abecasis; A-M Vandamme; R J Camacho
Journal:  J Antimicrob Chemother       Date:  2012-09-30       Impact factor: 5.790

3.  In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine.

Authors:  Susan M Schader; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Susan P Colby-Germinario; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

4.  The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

Authors:  Bluma G Brenner; Dimitrios Coutsinos
Journal:  HIV Ther       Date:  2009-11-01

5.  Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.

Authors:  Kristof Theys; Kristel Van Laethem; Perpetua Gomes; Guy Baele; Andrea-Clemencia Pineda-Peña; Anne-Mieke Vandamme; Ricardo J Camacho; Ana B Abecasis
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-29       Impact factor: 2.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.